secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001193125-25-226878
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi enters LNP license with Acuitas, terminates Affini-T TCR deal
------------------------------------------------------------------------

- Non-exclusive Acuitas license for LNP technology; low-seven-figure annual maintenance fee until first Phase 1 dosing.
- Milestone payments low to mid seven figures for regulatory/commercial events; royalties low mid-single digit % of net sales.
- Terminated Affini-T agreement effective Sept 30, 2025 due to Affini-T's assignment for benefit of creditors.
- Metagenomi regains full control over IP and rights to develop TCR-based therapeutics previously licensed to Affini-T.
- No future payments expected from Affini-T under terminated agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/0001193125-25-226878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/mgx-20250929.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-226878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer